254
Participants
Start Date
September 8, 2023
Primary Completion Date
December 1, 2025
Study Completion Date
December 30, 2025
SPH4336 Tablets
SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
SPH4336 Tablets Placebo
SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Jilin Cancer Hospital, Changchun
RECRUITING
Harbin Medical University cancer Hospital, Harbin
RECRUITING
Jiangsu Cancer Hospital, Nanjing
RECRUITING
Jiangsu Province Hospital, Nanjing
RECRUITING
Zhejiang cancer Hospital, Hangzhou
RECRUITING
Xiangyang Cancer Hospital, Wuhan
RECRUITING
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
RECRUITING
Anyang Cancer Hospital, Anyang
RECRUITING
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
Liuzhou people's Hospital, Liuzhou
RECRUITING
The second people's hospital of neijiang, Neijiang
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
RECRUITING
General Hospital of Ningxia Medical University, Yinchuan
RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
First Affiliated Hospital of Kunming Medical University, Kunming
RECRUITING
Shenzhen Hospital of University of Hong Kong, Shenzhen
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY